fe-LOE-di-peen
Therapeutic Classification: antianginals, antihypertensives
Pharmacologic Classification: calcium channel blockers
Absorption: Well absorbed after oral administration, but extensively metabolized, resulting in ↓ bioavailability.
Distribution: Unknown.
Protein Binding: >99%.
Half-Life: 11–16 hr.
Contraindicated in:
Use Cautiously in:
CV: peripheral edema, ARRHYTHMIAS, chest pain, HF, hypotension, palpitations, syncope, tachycardia
Derm: ↑sweating, dermatitis, erythema multiforme, flushing, photosensitivity, pruritus/urticaria, rash
EENT: blurred vision, disturbed equilibrium, epistaxis, tinnitus
Endo: gynecomastia, hyperglycemia
GI: ↑liver enzymes, anorexia, constipation, diarrhea, dry mouth, dysgeusia, dyspepsia, nausea, vomiting
GU: dysuria, nocturia, polyuria, sexual dysfunction, urinary frequency
Hemat: anemia, leukopenia, thrombocytopenia
MS: joint stiffness, muscle cramps
Neuro: headache, abnormal dreams, anxiety, confusion, dizziness, drowsiness, nervousness, paresthesia, psychiatric disturbances, tremor, weakness.
Misc: gingival hyperplasia, STEVENS-JOHNSON SYNDROME
Drug-drug:
Lab Test Considerations:
NDC Code